Barclays upgraded shares of Illumina (NASDAQ:ILMN) from an underweight rating to an equal weight rating in a research note released on Tuesday, Analyst Price Targets reports. The firm currently has $412.00 price objective on the life sciences company’s stock, down from their previous price objective of $432.72.
ILMN has been the topic of a number of other reports. TheStreet lowered Illumina from a b- rating to a c rating in a research note on Wednesday, October 6th. SVB Leerink increased their target price on Illumina from $420.00 to $430.00 and gave the stock a market perform rating in a research report on Tuesday. Bank of America raised Illumina from an underperform rating to a neutral rating and set a $390.00 price objective for the company in a research report on Friday, January 7th. Robert W. Baird cut their target price on Illumina from $493.00 to $437.00 and set a neutral rating on the stock in a research note on Monday, November 8th. Finally, Citigroup cut their target price on Illumina from $450.00 to $400.00 and set a neutral rating on the stock in a research note on Thursday, January 6th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of Hold and an average price target of $443.69.
ILMN opened at $405.14 on Tuesday. The firm has a market cap of $63.32 billion, a P/E ratio of 66.53, a price-to-earnings-growth ratio of 3.22 and a beta of 0.90. Illumina has a 52-week low of $341.03 and a 52-week high of $555.77. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.24 and a current ratio of 2.68. The business’s fifty day moving average is $378.55 and its 200-day moving average is $428.48.
In related news, SVP Charles Dadswell sold 314 shares of Illumina stock in a transaction dated Friday, October 22nd. The stock was sold at an average price of $411.00, for a total value of $129,054.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Alexander Aravanis sold 2,926 shares of Illumina stock in a transaction dated Tuesday, October 19th. The stock was sold at an average price of $411.82, for a total value of $1,204,985.32. The disclosure for this sale can be found here. Insiders sold 12,189 shares of company stock worth $5,024,576 over the last ninety days. Insiders own 0.23% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Evermay Wealth Management LLC bought a new position in Illumina in the second quarter worth approximately $26,000. Assetmark Inc. acquired a new position in shares of Illumina during the third quarter worth $26,000. Logan Capital Management Inc. increased its position in shares of Illumina by 90.7% during the third quarter. Logan Capital Management Inc. now owns 82 shares of the life sciences company’s stock worth $33,000 after purchasing an additional 39 shares in the last quarter. Activest Wealth Management acquired a new position in shares of Illumina in the 2nd quarter valued at $35,000. Finally, Bell Investment Advisors Inc acquired a new position in shares of Illumina in the 3rd quarter valued at $37,000. Hedge funds and other institutional investors own 84.89% of the company’s stock.
Illumina, Inc engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions.
Further Reading: Golden Cross
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.